Journal ArticleDOI
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
Maria Trojano,Damiano Paolicelli,Carla Tortorella,Piero Iaffaldano,Guglielmo Lucchese,Vita Di Renzo,Mariangela D'Onghia +6 more
Reads0
Chats0
TLDR
Whether DMDs may significantly alter the development of long-term disability remains uncertain, thus it remains challenging how to best approach the issue ofLong-term benefits from these treatments.About:
This article is published in Neurologic Clinics.The article was published on 2011-05-01. It has received 30 citations till now. The article focuses on the topics: Glatiramer acetate.read more
Citations
More filters
Journal ArticleDOI
Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.
TL;DR: HSCT, when used to treat patients with aggressive highly active multiple sclerosis, can reduce or eliminate ongoing clinical relapses, halt further progression, and reduce the burden of disability in some patients, in the absence of chronic treatment with disease-modifying agents.
Journal ArticleDOI
Facilitating Medication Adherence in Patients with Multiple Sclerosis
TL;DR: This article reviews adherence to medication in multiple sclerosis patients from the perspective of nurse and social worker authors and offers practical, evidence-based strategies that health-care providers can use to facilitate adherence.
Journal ArticleDOI
Fatigue, depression, and health-related quality of life in patients with multiple sclerosis in Isfahan, Iran
TL;DR: The aim of this study is to explore physical, psychological, and social aspects of health‐related QoL of MS patients in association with physical disability, fatigue, and depression.
Journal ArticleDOI
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines.
Bassem Yamout,Mohammed A. Sahraian,Saeed Bohlega,Mohammed Aljumah,R. Goueider,Maurice Dahdaleh,Jihad Inshasi,Saher Hashem,I. Alsharoqi,Samia J. Khoury,Mona AlKhawajah,S. Koussa,J. Al Khaburi,A. Almahdawi,Taoufik Alsaadi,E. Slassi,S Daodi,Magd Zakaria,Raed Alroughani +18 more
TL;DR: The purpose of these guidelines is to provide practical recommendations and algorithms for the diagnosis and treatment of MS based on current scientific evidence and clinical experience.
Journal ArticleDOI
Dietary interventions for multiple sclerosis‐related outcomes
TL;DR: Assessment of the effects of dietary interventions compared to placebo or another intervention on health outcomes (including MS-related outcomes and serious adverse events) in people with MS found there may be little to no difference in global impression of deterioration.
References
More filters
Journal ArticleDOI
The central role of the propensity score in observational studies for causal effects
TL;DR: The authors discusses the central role of propensity scores and balancing scores in the analysis of observational studies and shows that adjustment for the scalar propensity score is sufficient to remove bias due to all observed covariates.
Journal ArticleDOI
Propensity score methods for bias reduction in the comparison of a treatment to a non‐randomized control group
TL;DR: The propensity score, defined as the conditional probability of being treated given the covariates, can be used to balance the variance of covariates in the two groups, and therefore reduce bias as mentioned in this paper.
Journal ArticleDOI
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
TL;DR: In this article, five subclasses defined by the estimated propensity score are constructed that balance 74 covariates, and thereby provide estimates of treatment effects using direct adjustment, and these subclasses are applied within sub-populations, and model-based adjustments are then used to provide estimates for treatment effects within these sub-population.
Journal ArticleDOI
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
Lawrence Jacobs,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Jack H. Simon,John J. Alam,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +25 more
TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Journal ArticleDOI
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.
Charles H. Hennekens,Julie E. Buring,JoAnn E. Manson,Meir J. Stampfer,Bernard Rosner,Nancy R. Cook,Charlene Belanger,Frances LaMotte,John Michael Gaziano,Paul M. Ridker,Walter C. Willett,Richard Peto +11 more
TL;DR: In this trial among healthy men, 12 years of supplementation with beta carotene produced neither benefit nor harm in terms of the incidence of malignant neoplasms, cardiovascular disease, or death from all causes.
Related Papers (5)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more